

Applicants . Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 27

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(c)(2)**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following publications which are listed again on the attached Form PTO-1449 (**Exhibit 9**) and copies of References 1-5 (**Exhibits 10-14**) are enclosed.

This Third Supplemental Information Disclosure Statement is being submitted after the issuance of a first Office Action on the merits in connection with the subject application, but prior to the issuance of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311 or an action that otherwise closes prosecution. Pursuant to 37 C.F.R. § 1.97(c)(2), the required fee for filing an Information Disclosure Statement is \$180.00 and a check in this amount is enclosed. Accordingly, this Third Supplemental Information Disclosure Statement shall be considered pursuant to 37 C.F.R. §1.97(c)(2).

1. U.S. Patent No. 3,991,210, issued November 9, 1976 (Shea) (**Exhibit 10**)
2. U.S. Patent Publication No. US-2002-0037848-A1, published March 28, 2002 (Eisenbach-Schwartz et al.) (**Exhibit 11**)
3. U.S. Patent Publication No. US-2002-0107388-A1, published August 8, 2002 (Vandenbark) (**Exhibit 12**)
4. U.S. Patent Publication No. US-2003-0004099-A1, published January 2, 2003 (Eisenbach-Schwartz et al.) (**Exhibit 13**);
and

Applicants . Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 28


5. Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", Current Opin. Immunol., 2000, 12(6): 704-711 (**Exhibit 14**).

Applicants request that the Examiner review the publications and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$390 (\$180.00 for the Third Supplemental Information Disclosure Statement and \$210 for the excess claims surcharge), is deemed necessary in connection with the filing of this Amendment and Third Supplemental Information Disclosure Statement. However, if any additional fee is deemed necessary, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

 6/25/03
John P. White Date
Reg. No. 28,678

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60807-A-PCT-US/ JPW/ GJG/CSN		Serial No. 09/816,989	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Alexander Gad and Dora Lis			
				Filing Date March 23, 2001		Group Art Unit 1644	

U.S. PATENT DOCUMENTS												
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate						
	US 3 9 9 1 2 1 0	11/09/76	Shea									
	US 20 02 00 37 84 8 A1	03/28/02	Eisenbach-Schwartz et al.									
	US 20 02 01 07 38 8 A1	08/08/02	Vandenbark									
	US 20 03 00 04 09 9 A1	01/02/03	Eisenbach-Schwartz et al.									

FOREIGN PATENT DOCUMENTS										
Document Number	Date	Country	Class	Subclass	Translation					
					Yes	No				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, 12(6): 704-711.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.